Agile Therapeutics reports Q2 adjusted EPS ($3.10) vs. ($135.46) last year

Reports Q2 revenue $5.5M vs. $2.1M last year. “We set single-quarter record highs in demand, net revenue and factory sales, all while reporting another quarterly decrease in operating expenses,” said Agile Therapeutics’ Chairperson and Chief Executive Officer Al Altomari. “We are beyond pleased with the second quarter 2023 results, but the job is not done, and our focus is on accelerating future growth and achieving 2023 net revenue of $25-$30 million. Strong, focused external relationships are an integral part of our business plan, and we expect to continue to explore collaborations that can positively impact our business, allow us to expand without incurring significant costs and promote a growing, sustainable, fiscally-responsible business,” added Chief Commercial Officer Amy Welsh. “The structure and strategy of our business plan is the foundation for our confidence in continued Twirla growth in the second half of 2023.”